'Equitable distribution': Covax says Serum bound to supply virus vaccines

The AstraZeneca vaccine, sold under the brand name Covishield | Photo: PTI
 The Serum Institute of India (SII) is legally compelled to ship coronavirus vaccine to global vaccine sharing facility COVAX, its co-lead Gavi has told Reuters, a provision that could complicate the firm's efforts to boost domestic supplies.

 
India, where infections have surged to 13.06 million, suspended all major exports of vaccines last month to fill demand at home, forcing the world's biggest vaccine maker to divert nearly all its production to the domestic market.

 
"The agreement is legally binding and served as a basis for the first-round allocation document, which has been communicated to all participating economies," a Gavi spokeswoman said in an email.

 
The pact specified Gavi would receive from SII 1.1 billion doses of either the AstraZeneca vaccine or that of Novavax , with 200 million committed, and the rest on option.

 
SII partner AstraZeneca has already issued it a legal notice over delays to other shipments, even as many Indian states have complained of a shortage facing priority recipients.

Gavi said its pact with SII took effect when the World Health Organization approved the AstraZeneca shot on Feb. 15, after a source said SII had originally been supposed to send doses to COVAX only from May.

 
"SII has pledged that, alongside supplying India, it will prioritise the COVAX multilateral solution for equitable distribution," Gavi added.

 
COVAX had expected a total of more than 100 million doses from SII between February and May, excluding supplies for India, but has so far received only about 18.2 million.

 
Serum has sent another 10 million doses to the Indian government through COVAX, Gavi said.

 
Gavi did not respond on Friday to questions about what now lies ahead. SII also did not immediately respond to a request for comment.

 
From an initial August target of vaccine coverage for 300 million of its highest-risk people, or just over a fifth of its population of 1.35 billion, India has upped the figure by about 100 million, adding pressure on SII to crank up supplies.

 
India could resume vaccine exports by June, the firm's chief executive, Adar Poonawalla, told media this week.

 
The firm has also sought $403 million from New Delhi as a grant to boost monthly output to more than 100 million doses by end-May, from 65 million to 70 million now.

 
On Thursday, the foreign ministry said domestic demand would determine the extent of India's exports. It has already shipped 64.5 million doses and given out 92 million at home.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel